Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activityWyndham H. Wilson, Rod Humerickhouse, Steven W. Elmore et al.|The Lancet Oncology|2010Cited by 852
Vitamin C Antagonizes the Cytotoxic Effects of Antineoplastic DrugsMark Heaney, Owen A. O’Connor|Cancer Research|2008Cited by 222
HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCLMatko Kalac, Owen A. O’Connor|Blood|2011Cited by 154
The Combination of the Proteasome Inhibitor Bortezomib and the Bcl-2 Antisense Molecule Oblimersen Sensitizes Human B-Cell Lymphomas to CyclophosphamideOwen A. O’Connor, Asher Chanan‐Khan|Clinical Cancer Research|2006Cited by 46
Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignanciesMatthew S. Davids, Ian W. Flinn, Owen A. O’Connor et al.|Blood Advances|2021Cited by 21